Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The global ventricular tachycardia devices market was valued at USD 1.95 Billion in 2025, driven by rising incidence of ventricular arrhythmias across the globe. It is expected to grow at a CAGR of 6.40% during the forecast period of 2026-2035 and attain a market value of USD 3.63 Billion by 2035.
Geopolitical Impact of Iran, US, and Israel War on the Ventricular Tachycardia Devices Market
United States: The Ventricular Tachycardia Devices Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Diesel costs have risen approximately 40% from late February to mid-March 2026, directly inflating operating costs for all freight and logistics operations. Jet fuel costs have nearly doubled. Regional airspace closures across Iran, Iraq, Israel, Bahrain, Kuwait, Qatar, UAE, and Syria are forcing airlines to reroute, adding 1-2 hours and significant fuel costs. Global ocean freight costs are up 30% from rerouting and war-risk insurance surcharges. Air cargo costs have risen approximately 10% per week since the conflict began. FedEx and UPS have suspended Middle East services. Major carriers including Maersk and Hapag-Lloyd are routing vessels around the Cape of Good Hope, adding 3,500 nautical miles and approximately USD 1M per voyage. U.S. freight costs are rising: UPS and FedEx fuel surcharges now run 23-27% and 25.5% respectively, with USPS filing its first-ever 8% emergency fuel surcharge on March 25.
Iran: Iran's domestic Ventricular Tachycardia Devices sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.
Israel: Israel's Ventricular Tachycardia Devices sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalise.
Government
Market
Procurement
Base Year
Historical Period
Forecast Period
The increasing incidence of ventricular arrhythmias among other congenital heart conditions is one of the main factors influencing the market value.
The strong backing from health regulators such as the FDA and ongoing research and development are expected to increase the market worth.
The growth in new drug approvals by regulatory agencies such as the United States FDA is a significant market trend.
Compound Annual Growth Rate
6.4%
Value in USD Billion
2026-2035
*this image is indicative*
Ventricular tachycardia devices include cardioverter-defibrillators (ICDs) and pacemakers, which are used to monitor and regulate fast heart rhythms coming from the ventricles. They play a vital role in controlling irregular heartbeats and avoiding unexpected heart failure. The market growth is fueled by the advancement in the treatment, increased investment, and support for cutting-edge research.
Rising Incidence of Ventricular Arrhythmias in Congenital Heart Disease to Drive the Market Growth
The increasing occurrence of ventricular arrhythmias in congenital heart disease is fueling the global demand for ventricular tachycardia devices, particularly in the pediatric population. The increasing prevalence of ventricular arrhythmias in patients with coronary heart disease showcases a greater need for medical devices such as pacemakers and defibrillators, leading to market expansion.
Advent of New Treatments to Boost the Ventricular Tachycardia Devices Market Demand
With the rising demand for treatments, the market for ventricular tachycardia devices is expanding. Technological and treatment advancement such as using exosomes from stem cells to improve treatments for venous thrombosis through cell-based therapy aims to overcome issues related to side effects and invasive procedures.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on the Product to Witness Growth
Based on the product, the market is segmented into implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-D), and directed energy-based therapy devices. Implantable cardioverter defibrillators are expected to lead the market as they can both act as pacemakers and prevent sudden death in patients with ventricular arrhythmias.
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The region that is most likely to dominate the market is North America, with Europe closely behind. Ventricular tachycardia and fibrillation are leading factors in sudden cardiac death, accounting for approximately 300,000 deaths in the United States each year. The rising incidence of the condition in the region is contributing to market growth.
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic plc, a medical technology company based in America and Ireland received the FDA approval to conduct a trial on its Affera mapping and ablation system and Sphere-9 catheter for managing sustained ventricular tachycardia. This marks a significant advancement in cardiac electrophysiology ablation procedures and reflects the company’s stronghold on the market.
Siemens Healthineers is a healthcare company based in Germany, focused on creating, developing, manufacturing, and delivering diagnostic imaging and clinical systems. Varian, a Siemens Healthineers subsidiary, started the RADIATE-VT1 clinical trial at the Washington University School of Medicine to assess cardiac radioablation for high-risk ventricular tachycardia patients.
Abbott Laboratories specializes in healthcare products, including pharmaceuticals, diagnostic systems, and nutrition. In January 2024, Abbott announced its entry into the global ventricular tachycardia devices market with its pulsed field ablation device, Volt, currently in clinical development. Targeting atrial fibrillation treatment, Volt aims to launch in the U.S. by 2026.
Biotronik, a Berlin-based multinational cardiovascular biomedical company, specializes in technology for cardiac rhythm management, electrophysiology, and vascular intervention. Notable for its implantable cardioverter-defibrillator devices like Inventra 7 VR-T DX and Acticor DX, the company plays a crucial role in the ventricular tachycardia device market, delivering electroshocks to treat tachycardia.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market are Asahi Kasei Corporation, Elekta AB, Boston Scientific Corporation, EBR Systems, Inc., Johnson & Johnson, LivaNova plc, Thermedical, Inc., and Schiller AG.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share